Purpose: There is increasing evidence that patients with PNES can form subgroups distinguished by emotion dysregulation and comorbid psychological symptoms. The purpose of this study was to determine if patients with comorbid PTSD differ from other patients with PNES in terms of alexithymia and stress coping strategies.

Methods: 156 adult patients with video-EEG confirmed PNES were assessed with the Trauma Symptom Inventory-2 (TSI-2) and diagnostic clinical interview, Toronto Alexithymia Scale (TAS-20), and the Coping Inventory for Stressful Situations (CISS). There were 3 groups: 48 patients with PTSD, 62 patients who had experienced trauma and did not have PTSD, and 46 patients who denied experiencing trauma.

Results: One-way ANCOVA revealed a significant difference between groups on reported levels of alexithymia [F(2, 154) = 18.21, p < .001] and use of emotion-focused coping [F(2, 156) = 11.12, p < .001]. Tukey HSD post-hoc comparisons indicated that the PNES/PTSD group had significantly higher mean alexithymia scores (M = 59.54, SD = 12.89) than both the no trauma (M = 49.51, SD = 14.92) and the trauma with no PTSD groups (M = 49.98, SD = 13.27), which did not differ from each other. The PNES/PTSD group was also significantly more likely (M = 62.44, SD = 11.56) than the no trauma (M = 52.87, SD = 13.57) and the trauma with no PTSD groups (M = 52.06, SD = 12.63) to utilize emotion-focused coping strategies. No significant differences were found between groups on use of task- or avoidance-focused coping.

Conclusion: The study revealed elevated alexithymia and use of potentially more maladaptive emotion-focused coping strategies among patients with PNES and comorbid PTSD. These findings highlight discrete areas to target in treatment depending on comorbid symptomatology, and suggests that PNES, which is often regarded as a homogeneous entity, appears to encompass distinct subgroups.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.seizure.2018.03.011DOI Listing

Publication Analysis

Top Keywords

patients
8
patients pnes
8
ptsd patients
8
post-traumatic stress
4
stress relationships
4
relationships coping
4
alexithymia
4
coping alexithymia
4
alexithymia patients
4
patients psychogenic
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biogen, Cambridge, MA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sage Bionetworks, Seattle, WA, USA.

Background: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Clario, Philadelphia, PA, USA.

Background: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.

Method: ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!